140 related articles for article (PubMed ID: 23757752)
1. Potential harms of type 2 diabetes drugs have been ignored, finds BMJ investigation.
Kmietowicz Z
BMJ; 2013 Jun; 346():f3782. PubMed ID: 23757752
[No Abstract] [Full Text] [Related]
2. Pancreatic safety of incretin-based drugs--FDA and EMA assessment.
Egan AG; Blind E; Dunder K; de Graeff PA; Hummer BT; Bourcier T; Rosebraugh C
N Engl J Med; 2014 Feb; 370(9):794-7. PubMed ID: 24571751
[No Abstract] [Full Text] [Related]
3. Incretins and risk of neoplasia.
Halfdanarson TR; Pannala R
BMJ; 2013 Jun; 346():f3750. PubMed ID: 23751908
[No Abstract] [Full Text] [Related]
4. Novo Nordisk replies to BMJ investigation on incretins and pancreatic damage.
Moses A
BMJ; 2013 Jul; 347():f4386. PubMed ID: 23842435
[No Abstract] [Full Text] [Related]
5. FDA is to assess data linking type 2 diabetes drugs with pancreatitis.
Cohen D
BMJ; 2013 Mar; 346():f1808. PubMed ID: 23512765
[No Abstract] [Full Text] [Related]
6. Q: Do incretin drugs for type 2 diabetes increase the risk of acute pancreatitis?
Olansky L
Cleve Clin J Med; 2010 Aug; 77(8):503-5. PubMed ID: 20682512
[No Abstract] [Full Text] [Related]
7. [Incretin-based antidiabetic treatment and diseases of the pancreas (pancreatitis, pancreas carcinoma)].
Jermendy G
Orv Hetil; 2016 Apr; 157(14):523-8. PubMed ID: 27017851
[TBL] [Abstract][Full Text] [Related]
8. Weighing risks and benefits of liraglutide--the FDA's review of a new antidiabetic therapy.
Parks M; Rosebraugh C
N Engl J Med; 2010 Mar; 362(9):774-7. PubMed ID: 20164475
[No Abstract] [Full Text] [Related]
9. Incretin-based glucose-lowering medications and the risk of acute pancreatitis and/or pancreatic cancer: Reassuring data from cardio-vascular outcome trials.
Nauck MA; Meier JJ; Schmidt WE
Diabetes Obes Metab; 2017 Sep; 19(9):1327-1328. PubMed ID: 28432752
[No Abstract] [Full Text] [Related]
10. Hyperplasia from GLP-1 drugs is "not a surprise," say researchers.
Cohen D
BMJ; 2013 Mar; 346():f2025. PubMed ID: 23535260
[No Abstract] [Full Text] [Related]
11. Pro- or anti-inflammatory properties of the adipokine dipeptidyl peptidase-4?
Xu L; Spinas GA; Niessen M
Gastroenterology; 2011 Dec; 141(6):e17. PubMed ID: 22036848
[No Abstract] [Full Text] [Related]
12. GLP-1-based therapies: the dilemma of uncertainty.
Spranger J; Gundert-Remy U; Stammschulte T
Gastroenterology; 2011 Jul; 141(1):20-3. PubMed ID: 21723985
[No Abstract] [Full Text] [Related]
13. Incretin-based pharmacotherapy and risk of adverse pancreatic events in the ethnic Chinese with diabetes mellitus: A population-based study in Taiwan.
Tseng CM; Liao WC; Chang CY; Lee CT; Tseng CH; Hsu YC; Lin JT
Pancreatology; 2017; 17(1):76-82. PubMed ID: 27743712
[TBL] [Abstract][Full Text] [Related]
14. Journal’s withdrawal of article. Paper OK, title wrong.
Moore N
BMJ; 2011 May; 342():d2732. PubMed ID: 21558338
[No Abstract] [Full Text] [Related]
15. Assessing the cardiovascular safety of diabetes therapies.
Goldfine AB
N Engl J Med; 2008 Sep; 359(11):1092-5. PubMed ID: 18784098
[No Abstract] [Full Text] [Related]
16. Preying on the pancreas? Scientists debate whether newer diabetes medications do harm.
Berg EG
Diabetes Forecast; 2013 Oct; 66(10):26, 28, 30-1. PubMed ID: 24224353
[No Abstract] [Full Text] [Related]
17. European Medicines Agency must take account of cardiovascular harm associated with degludec insulin.
Schmidt TA; Rosen CJ; Yudkin JS
BMJ; 2013 Jun; 346():f3731. PubMed ID: 23757746
[No Abstract] [Full Text] [Related]
18. Journal withdraws article after complaints from drug manufacturers.
Hawkes N
BMJ; 2011 Apr; 342():d2335. PubMed ID: 21482597
[No Abstract] [Full Text] [Related]
19. The safety of incretin based drug treatments for type 2 diabetes.
Bolen SD; Maruthur NM
BMJ; 2016 Feb; 352():i801. PubMed ID: 26888024
[No Abstract] [Full Text] [Related]
20. Pancreatitis and incretin-based drugs: clarity or confusion?
Nauck MA; Meier JJ
Lancet Diabetes Endocrinol; 2014 Feb; 2(2):92-3. PubMed ID: 24622699
[No Abstract] [Full Text] [Related]
[Next] [New Search]
